Solitary benign peripheral-nerve tumours are rare and may be difficult to diagnose correctly. Surgical excision may increase the patient's symptoms and may not be necessary. We have reviewed the presentation, clinical findings and histology of 104 solitary tumours presenting at one centre between 1959 and 1990. Male patients predominated for both schwannoma and neurofibroma. There was considerable but variable delay before presentation; 94% of patients complained primarily of a mass and less than half had pain or paraesthesia. The correct diagnosis had been made in only a few cases before operation, and the incidence of neurological symptoms doubled after exploration. We emphasise the need for vigilance, accurate preoperative diagnosis, and careful surgery.

and g sarcoma. Eight of these cases are described i n detail and are accompanied by illustrations to show some of the types of tumour found and the complications which may occur.M y thanks are due to my colleagues of the Western Infirmary Staff, named in the text, for allowing m e to use their cases and for their ready help and co-operation; to Mr. Roy F. Yoimg and Prof. Illingworth for the use of their cases and for their assistance with this paper; and to members of the Staff of the Pathology Department of the Western Infirmary, particularby to Dr. Alan C. Lendrum, for kindly comments and most of the ideas incorporated in the discusslion of the sarcomata.The illustrations are the work of Miss C. Brown Kelly and D r . N. Cowan; the phocomicrographs are by Mr. John W a t t : to these I a m greatly indebted for their care.

This article is the second of a two-part series on GuardIVa®, a novel antimicrobial haemostatic IV dressing from HemCon Medical Technologies. In Part 1 ( Donnellan et al, 2011 ), the ability of GuardIVa Antimicrobial Haemostatic IV Dressing to significantly suppress skin flora re-growth was demonstrated in a clinical study conducted with healthy human volunteers. In addition, the antimicrobial and haemostatic efficacy of the dressing and its effects on wound healing were presented following a number of independently conducted in-vitro and in-vivo tests. In Part 2, the dressing was assessed for use as part of dressing change kits for patients with temporary short-term catheters in the intensive care unit (ICU) of a major US hospital. The use of GuardIVa Antimicrobial Haemostatic IV Dressing by a wound care nurse on a high level functioning quadriplegic patient presenting with redness, fluid and bleeding at the access site of a percutaneous medical device was also assessed. The positive outcomes from these experiences demonstrate that the GuardIVa dressings may be used as an effective component of catheter site regimens implemented by health professionals in a range of medical applications in diverse facilities.